

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ACRUX DDS PTY LTD. & ACRUX LIMITED
Petitioners

v.

KAKEN PHARMACEUTICAL CO., LTD. and
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
Patent Owner and Licensee

Patent No. 7,214,506
Issue Date: May 8, 2007
Title: Method for Treating Onychomycosis

DECLARATION OF KENNETH A. WALTERS, PH.D.

TABLE OF CONTENTS

I.	Qualifications, Background, and Experience	1
II.	Scope of Assignment	6
III.	Materials Considered	7
IV.	Summary of Opinions	13
V.	Legal Principles Used in Analysis	14
A.	Patent Claims in General	14
B.	Person of Ordinary Skill in the Art	15
C.	Claim Construction	16
D.	Prior Art	16
E.	Priority	17
F.	Patentability	17
VI.	A Person of Ordinary Skill in the Relevant Art	21
A.	Relevant Field	21
B.	Person of Ordinary Skill in the Art	21
VII.	Background of the Relevant Technology	22
VIII.	The '506 Patent	26
A.	The Claims of the '506 Patent	30
B.	Problem Addressed by the '506 Patent	31
C.	Solution Set Forth in the '506 Patent	33
IX.	Priority Date of the '506 Patent	37
X.	Obviousness Analysis	40
A.	Summary of Opinions	40
B.	Ground 1: The Methods of Claims 1 and 2 of the '506 Patent Would Have Been Obvious Over Japanese Pat. App. Pub. No. 10-226639 in View of Ogura	42
i.	Summary of JP '639	42
ii.	Summary of Ogura	45

iii.	The Combination of JP '639 and Ogura	46
C.	Ground 2: The Methods of Claims 1 and 2 of the '506 Patent Would Have Been Obvious Over U.S. Pat. No. 5,391,367 in View of Ogura	49
i.	Summary of the '367 Patent	49
ii.	Summary of Ogura.....	50
iii.	The Combination of the '367 Patent and Ogura.....	51
D.	Ground 3: The Methods of Claims 1 and 2 of the '506 Patent Would Have Been Obvious Over Hay 1985 in View of Ogura	53
i.	Summary of Hay 1985	53
ii.	Summary of Ogura.....	54
iii.	The Combination of Hay 1985 and Ogura.....	54
E.	Ground 4: The Methods of Claims 1 and 2 of the '506 Patent Would Have Been Obvious Over JP '639 in view of the Kaken Abstracts	57
i.	Summary of JP '639	57
ii.	Summary of the Kaken Abstracts	57
iii.	The Combination of JP'639 and the Kaken Abstracts.....	58
F.	Ground 5: The Methods of Claims 1 and 2 of the '506 Patent Would Have Been Obvious over the '367 Patent in View of the Kaken Abstracts.....	61
i.	Summary of the '367 Patent	61
ii.	Summary of the Kaken Abstracts	61
iii.	The Combination of the '367 Patent and the Kaken Abstracts.....	62
G.	Ground 6: The Methods of Claims 1 and 2 of the '506 Patent Would Have Been Obvious over the Hay 1985 in view of the Kaken Abstracts.....	64
i.	Summary of Hay 1985	64
ii.	Summary of the Kaken Abstracts	64
iii.	The Combination of Hay 1985 and the Kaken Abstracts	64
H.	Secondary Considerations	66

i.	The Alleged Unexpected Results Relied on by the Applicants During Prosecution Were Actually Known Beneficial Results of the Use of KP-103	67
ii.	The Data Presented in the '506 Specification is Flawed and Does Not Provide Evidence of an Unexpected Effect.....	70
iii.	Contrary to the Applicants' Argument During Prosecution, the Data Demonstrate That the Claimed Compounds Do Not Eradicate the Infection.	73
I.	Claim Charts.....	76
XI.	Conclusions.....	76

1. My name is Kenneth A. Walters. I was the Director of Research and Development and Business Development and am currently the Director of QA/QC at An-eX Analytical Services Limited in Cardiff, United Kingdom (“An-eX”). An-eX is an independent contract research and development company that offers a range of dermatological and transdermal services to the pharmaceutical, cosmetic, chemical and agrochemical industries. I understand that my declaration is being submitted in connection with a Petition for *Inter Partes* Review of U.S. Patent No. 7,214,506 (the “506 patent”) (Ex. 1001).

I. Qualifications, Background, and Experience

2. I received CBiol and MIBiol degrees in physiology/pharmacology from Stockport Technical College (now Stockport College) in Stockport (United Kingdom) in 1973, a Ph.D. in Toxicology from University of Strathclyde in Glasgow (United Kingdom) in 1978. I held a post-doctoral position at the University of Michigan from 1978-1980 focusing on transungual delivery. I also held a post-doctoral position at the University of Bath (United Kingdom) from 1980-1981 focusing on pharmaceutical formulations. I am currently an elected Fellow of the Royal Society of Biology.

3. I have edited or co-edited 9 scientific and technical books and authored or co-authored over 100 scientific and technical journal articles and book

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.